If you're a fan of both small caps and tech shares then you're in luck. Right now, there are a number trading on the ASX market that have a lot of growth potential.
Two that could be worth keeping a close eye on are listed below. Here's what you need to know about them:
Bigtincan Holdings Ltd (ASX: BTH)
Bigtincan is a provider of enterprise mobility software to sales and service organisations. It has been designed to allow users to increase sales win rates, reduce expenditures, and improve customer satisfaction through improved mobile worker productivity.
Demand has been strong for its platform. This includes from some of the biggest companies in the world, which has underpinned very strong recurring revenue growth.
The company recently released its third quarter update and revealed that it is forecasting its annualised recurring revenue (ARR) to be at the top end of its FY 2021 guidance range of $49 million to $53 million. This compares to FY 2020's ARR of $35.8 million, representing year on year growth of 36.9% to 48%.
Earlier this month, Morgan Stanley put an overweight rating and $1.50 price target on the company's shares.
Volpara Health Technologies Ltd (ASX: VHT)
Another small cap tech share to watch is Volpara. It is a healthcare technology company that provides software which leverages artificial intelligence imaging algorithms to help with the early detection of breast cancer.
The company notes that its innovative products have an ever-increasing number of patents, trademarks, and regulatory clearances, including FDA clearance and CE marking. They are also validated by a volume of peer-reviewed publications and unrivalled in the breast screening industry.
Volpara has been a very strong performer in recent years and has consistently grown its market share in the United States. Pleasingly, it appears well-placed for more of the same in the coming years thanks to the quality of its offering and recent acquisitions and developments. Combined with increases in its average revenue per user metric, this could underpin strong revenue growth over the next decade.
Morgans is a fan of the company. It currently has an add rating and $1.94 price target on its shares.
